March 09, 2026

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

Conexiant

March 09, 2026

CDC Mobilizes Federal Support for Measles Outbreaks

Federal disease detectives deploy to South Carolina as CDC expands its multistate containment strategy

Conexiant

March 02, 2026

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

Conexiant

March 02, 2026

Coverage Isn’t Access: Medicaid’s Dilemma

As more states expand adult Medicaid dental benefits, participation remains low and GOP-backed federal cuts threaten to reverse recent progress, raising concerns for physicians and dentists.

KFF Health News

February 27, 2026

ACOG Parts Ways With ACIP

“ACOG’s withdrawal from ACIP is not a withdrawal from our commitment to advancing vaccine science or to protecting patients’ health and safety."

Conexiant

February 27, 2026

MHRA Approval for First UK-made mRNA Vaccine

Moderna receives MHRA approval for updated COVID-19 vaccine targeting SARS-CoV-2 variant LP.8.1

The Medicine Maker

February 25, 2026

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

Conexiant

February 23, 2026

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

Conexiant

February 18, 2026

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Conexiant

February 17, 2026

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

Conexiant